27 related articles for article (PubMed ID: 12955471)
21. [Clinical pharmacology of idarubicin].
Robak T
Acta Haematol Pol; 1993; 24(4):315-26. PubMed ID: 8303977
[TBL] [Abstract][Full Text] [Related]
22. Pharmacogenetic considerations for non-Hodgkin's lymphoma therapy.
Espirito Santo A; Medeiros R
Expert Opin Drug Metab Toxicol; 2013 Dec; 9(12):1625-34. PubMed ID: 24053936
[TBL] [Abstract][Full Text] [Related]
23. Increased myelotoxicity of idarubicin: is there a pharmacological basis? Results of a pharmacokinetic and an in vitro cytotoxicity study.
Kroschinsky F; Schleyer E; Renner U; Schimming C; Schimmelpfennig C; Bornhäuser M; Illmer T; Trümper L; Ehninger G; Schaich M
Cancer Chemother Pharmacol; 2004 Jan; 53(1):61-7. PubMed ID: 12955471
[TBL] [Abstract][Full Text] [Related]
24. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.
Tamura K
Semin Hematol; 1996 Oct; 33(4 Suppl 3):2-11. PubMed ID: 8916310
[TBL] [Abstract][Full Text] [Related]
25. Modulation of P-glycoprotein function and reversal of multidrug resistance by (-)-epigallocatechin gallate in human cancer cells.
Qian F; Wei D; Zhang Q; Yang S
Biomed Pharmacother; 2005 Apr; 59(3):64-9. PubMed ID: 15795098
[TBL] [Abstract][Full Text] [Related]
26. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
27. Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results.
Leoni F; Ciolli S; Giuliani G; Pascarella A; Caporale R; Salti F; Cervi L; Rossi Ferrini P
Br J Haematol; 1995 May; 90(1):169-74. PubMed ID: 7786781
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
